trending Market Intelligence /marketintelligence/en/news-insights/trending/c1YCgV7OJmaBep7wSpOG7Q2 content esgSubNav
In This List

Report: AstraZeneca's lung cancer drug greenlit in China

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Report: AstraZeneca's lung cancer drug greenlit in China

AstraZeneca PLC received approval from China's Food and Drug Administration to market its new lung cancer drug Tagrisso in the country, Bloomberg News reported, citing the company's announcement on its WeChat account.

The approval comes as the Chinese regulator vowed to hasten drug approvals, and is considering simplifying requirements for international clinical trials.

Representatives from the drugmaker couldn't immediately be reached for comment, according to the report.